Changeflow GovPing Healthcare & Life Sciences FDA CDER Acknowledgment Letter to Annora Pharma
Routine Notice Added Final

FDA CDER Acknowledgment Letter to Annora Pharma

Email

Summary

FDA CDER issued an acknowledgment letter to Annora Pharma Private Limited dated April 24, 2026. The acknowledgment appears in connection with docket FDA-2026-P-4574, indicating receipt of a pre-submission package or IND submission for review. No substantive regulatory determinations or compliance obligations are contained in this acknowledgment document.

Published by FDA CDER on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

FDA CDER issued an acknowledgment letter to Annora Pharma confirming receipt of a submission associated with docket FDA-2026-P-4574. The acknowledgment letter represents a procedural administrative step, confirming that the agency has received and is processing Annora Pharma's submission. No substantive review findings, approval decisions, or compliance requirements are contained in this acknowledgment. Affected parties should await further substantive correspondence from FDA CDER regarding their submission status.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

There are no documents available to view or download

Attachments 1

Acknowledgment Letter from FDA CDER to Annora Pharma Private Limited

More Information
- Author(s) CDER
Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA CDER.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA CDER
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4574

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Regulatory submission IND submission process
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!